Arecor Therapeutics PLC ARECOR COLLABORATES WITH TOP GLOBAL PHARMA COMPANY (0563P)
16 June 2022 - 4:00PM
UK Regulatory
TIDMAREC
RNS Number : 0563P
Arecor Therapeutics PLC
16 June 2022
Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR ANNOUNCES EXCLUSIVE COLLABORATION WITH A TOP 5 GLOBAL
PHARMACEUTICAL COMPANY
Development of stable injectable high concentration formulations
for its proprietary products
Cambridge, UK, 16 June 2022: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, today announces that it has signed an
exclusive formulation study collaboration with a top five global
pharmaceutical company.
Under the terms of the agreement, Arecor will use its
proprietary formulation technology platform, Arestat(TM), to
develop improved, stable, high concentration liquid formulations of
its proprietary products. The Company will fund the initial
development work and has the option to acquire the rights to the
new proprietary formulations and associated intellectual property
under a technology licensing model.
Sarah Howell, Chief Executive Officer of Arecor, said: "This
collaboration expands our partner portfolio of high-profile
pharmaceutical companies. The growing recognition of how the
Arestat(TM) platform can enhance a broad range of therapeutic
products is testament to our expertise and innovation in
formulation science. For our partners, we are able to significantly
improve their products to enable patient friendly treatment
regimens that are effective, safe and more convenient, which in
turn can lead to better adherence and health outcomes, benefitting
healthcare systems as a whole."
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary formulation technology
platform, Arestat(TM), we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat(TM) platform is supported by an extensive patent
portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFAMLTMTBBBJT
(END) Dow Jones Newswires
June 16, 2022 02:00 ET (06:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2023 to Apr 2024
